Redwire Chief Scientist Dr. Kenneth Savin Named to TIME's 2025 TIME100 Health List of the 100 Most Influential People in Global Health
Dr. Savin was selected for his deep expertise in the pharmaceutical industry and his pioneering work accelerating cutting-edge space biotech research capabilities, which leverage microgravity to improve human health on Earth. At Redwire, Dr. Savin has overseen trailblazing investigations onboard the International Space Station (ISS) in partnership with NASA and the ISS National Laboratory. Redwire successfully bioprinted the first human knee meniscus and first live human cardiac tissue using its BioFabrication Facility on the ISS. These breakthroughs address challenges faced by millions of people worldwide through the application of organ transplantation and tissue therapy and advance the next generation of pharmaceutical therapies.
Dr. Savin has coordinated groundbreaking protein crystallization investigations onboard the ISS with pharmaceutical companies like Eli Lilly and Company (Lilly) and Bristol Myers Squibb using Redwire's in-space pharmaceutical lab, PIL-BOX, for improved drug development. These investigations have focused on various applications to address the world's most prevalent conditions, including antiviral, antifungal, and antiseizure applications, heart disease, and bone loss.
'I am deeply honored to be recognized as one of the TIME100's most influential figures in health for 2025,' said Dr. Savin. 'Through microgravity research and development, we are seeing extraordinary scientific achievements that are accelerating game changing biomedical breakthroughs not possible on Earth and with enormous potential for the future of human health. I am honored and proud to be part of the Redwire team and excited to see what we are able to accomplish next."
Before joining Redwire, Dr. Savin had a successful 20-year career in the pharmaceutical industry working at Lilly, where he led various research and development teams, along with five investigations onboard the ISS. Following his time at Lilly, Dr. Savin was the Senior Director of In-Space Production Applications at the Center for the Advancement of Science In Space (manager of the ISS National Lab), where he worked with NASA to develop the In Space Production and Applications program to develop products in space that will benefit life on the Earth.
The full TIME100 Health list can be found here.
About Redwire
Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire's proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire's approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Cinemark to Dual List Common Stock on NYSE Texas
PLANO, Texas, August 18, 2025--(BUSINESS WIRE)--Cinemark Holdings, Inc. ("Cinemark") (NYSE: CNK), one of the largest and most influential theatrical exhibition companies in the world, today announced the dual listing of its common stock on NYSE Texas, the newly launched, fully electronic equities exchange headquartered in Dallas, Texas. Cinemark has been listed on the New York Stock Exchange (NYSE) since 2007, and this dual listing further strengthens its longstanding relationship with the exchange. Cinemark will retain its primary listing on the NYSE and will trade under the ticker symbol "CNK" on both exchanges. "We have a deep-rooted presence in Texas - with more than 25% of our domestic theaters in the Lone Star State, our company service center in Plano, and thousands of team members serving millions of guests throughout the state each year," said Sean Gamble, Cinemark President and CEO. "We are thrilled to further strengthen our connection to Texas through our dual listing on NYSE Texas while supporting the state's expanding financial ecosystem and providing opportunities for investors focused on localized, regional market opportunities." "As a leading movie theater company based in Texas, Cinemark is a natural addition to our community of NYSE Texas Founding Members," said Bryan Daniel, President, NYSE Texas. About Cinemark Holdings, Inc.: Headquartered in Plano, TX, Cinemark (NYSE: CNK) is one of the largest and most influential movie theater companies in the world. Cinemark's circuit, comprised of various brands that also include Century, Tinseltown and Rave, as of June 30, 2025 operated 497 theaters with 5,647 screens in 42 states domestically and 13 countries throughout South and Central America. Cinemark consistently provides an extraordinary guest experience from the initial ticket purchase to the closing credits, including Movie Club, the first U.S. exhibitor-launched subscription program; the highest Luxury Lounger recliner seat penetration among the major players; XD - the No. 1 exhibitor-brand premium large format; and expansive food and beverage options to further enhance the moviegoing experience. For more information go to View source version on Contacts Investor Contact: Chanda Brashearscbrashears@ Media Contact: Caitlin Piperpr@
Yahoo
a few seconds ago
- Yahoo
Mizuho Boosts Dell (DELL) Price Target on Strong FY26-FY27 Outlook
Dell Technologies Inc. (NYSE:DELL) is one of the On August 13, Mizuho analyst Vijay Rakesh raised the price target on the stock to $160.00 (from $150.00) while maintaining an Outperform rating. The firm increased estimates in the global artificial intelligence server group to reflect substantial ramps from the leading hyperscalers. The firm sees Rubin as a tailwind into the second half of 2026. It has maintained its July quarter revenue and earnings per share estimates, while raising its fiscal 2026 estimates and fiscal 2027 projections. It also lifted its AI server revenue forecasts for fiscal years 2026 and 2027 driven by benefits from increasing AI server deployments. This includes xAI's Colossus 2 ramp-up and anticipated capital expenditure increases from CRWV in the second half of 2025. Photo by Its me Pravin on Unsplash 'No change to our JulQ rev/EPS estimates at $29.0B/$2.25 (cons. $29.2B/$2.29), while we are raising F26E from $105B/$9.40 to $106B/$9.45 (cons. $105B/$9.39), F27E from $115B/$11.00 to $116B/$11.10 (cons. $112B/$10.81), AI Server revenues for F26/27E from $16.0B/$21.5B to $16.6B/$22.0B (cons. $16.0B/$21.0B).' Dell Technologies Inc. (NYSE:DELL) provides IT solutions, including servers, storage, networking, and personal computing devices, to businesses and consumers worldwide. While we acknowledge the potential of DELL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
a few seconds ago
- Yahoo
Why Rosenblatt Still Likes Coherent (COHR) Despite Competitive Pressure
Coherent Corp. (NYSE:COHR) is one of the . On August 14, Rosenblatt lowered the firm's price target on the stock to $135 from $150 and kept a Buy rating on the shares. The rating affirmation follows Coherent's fiscal Q4 report. According to Rosenblatt, the company tends to guide conservatively. However, it does not see any fundamental impairment to the positive thesis following the earnings report. The firm did acknowledge that competitor Lumentum has gained steam with its stronger near-term performance in laser chip, OCS, and CPO sales categories. 'We would note that Coherent management tends to guide conservatively. We do not think there is a fundamental impairment to the positive thesis. Lumentum has grabbed the momentum with stronger relative near-term performance in laser chip, OCS, and CPO sales. Nevertheless, we like the industry thesis and competitive environment, and think both LITE and COHR will do well.' A financial analyst poring over market data, projecting the company's futur investments. Even though Coherent is subject to this competitive pressure, Rosenblatt anticipates it to 'catch up in these key AI Optical categories over the course of FY26 and into FY27.' Moreover, it believes both Lumentum and Coherent will execute well in the industry. Coherent Corp. (NYSE:COHR) is an American manufacturer of optical materials and semiconductors. While we acknowledge the potential of COHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
